Contact Congress about H.R. 4273: Over-the-Counter Monograph Drug User Fee Amendments

Drug makers would keep paying FDA fees for many over-the-counter medicines through 2030. The bill updates fee amounts, due dates, yearly reports, and some review rules.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Over-the-Counter Monograph Drug User Fee Amendments is a House bill waiting for floor action. The latest recorded action: Placed on the Union Calendar, Calendar No. 254.

Latest action on H.R. 4273: Placed on the Union Calendar, Calendar No. 254.

Who this affects: This bill mainly affects companies and facilities that make over-the-counter drugs under FDA monographs. They would keep paying FDA fees and may face changed fee amounts or payment dates. It also affects the FDA, which uses the money to review, update, and oversee these drug standards. Consumers could be affected indirectly, but the bill does not say whether prices or product availability would change.

Why this matters: This matters because FDA oversight of many common over-the-counter medicines depends partly on these fees. The bill keeps that funding in place through 2030 and changes how the FDA adjusts fees over time. That could affect how steady the program is for both the FDA and drug makers. The bill does not say whether consumers would pay more or see fewer products.

Key provisions in H.R. 4273

• The FDA could keep collecting these over-the-counter drug fees through fiscal year 2030. Current authority covered fiscal years 2021 through 2025.
• Yearly facility fees would start with a base amount. The FDA would then adjust that amount for inflation, reserve needs, direct costs, and fixed increases for 2026 through 2028.
• The Secretary of Health and Human Services must set the yearly facility and order request fees early. The fees must be set at least 60 days before the fiscal year and published in the Federal Register, the official public notice system.
• The bill sets different due dates for different years. It uses a later-of rule for 2026, two half-payments for 2027, and an on-or-after October 1 due date for 2028 and later if Congress has approved funding.
• The FDA could use one workload fee increase in 2028, 2029, or 2030. It can happen only if the three-year average of fee-liable facilities is above 1,625 and less than 30% are behind on payments.

How Modern Action helps you take action on H.R. 4273

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 4273

What is H.R. 4273?

Drug makers would keep paying FDA fees for many over-the-counter medicines through 2030. The bill updates fee amounts, due dates, yearly reports, and some review rules.

How do I support or oppose H.R. 4273?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 4273?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain H.R. 4273 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.